<DOC>
	<DOCNO>NCT01020123</DOCNO>
	<brief_summary>The primary aim evaluate Efficacy , Safety Tolerability AZD1656 Add-on Treatment Metformin TD2M Patients</brief_summary>
	<brief_title>Evaluate Efficacy , Safety Tolerability AZD1656 Add-on Treatment Metformin Type 2 Diabetes Mellitus ( TD2M ) Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Glipizide</mesh_term>
	<criteria>female nonchildbearing potential Treated maximally tolerate dose metformin ( ≥ 1500mg/day ) least 10 week prior enrolment . Patients HbA1c ≥ 7.5 ≤ 10 % enrolment visit ( Visit 1 ) enter cohort 1.Patients HbA1c &gt; 10 % &lt; 12 % enter openlabel arm AZD1656 ( cohort 2 ) Significant cardiovascular event within last 6 month prior enrolment heart failure New York Heart Association ( NYHA ) class IIIIV . Impaired renal function term GFR &lt; 60 ml/min , base Modification Diet Renal Disease Study Group ( MDRD ) calculation . Use warfarin amiodarone within 3 month prior enrolment ( screen ) use potent CYP450 inhibitor , eg , ketoconazole and/or macrolide antibiotic within 14 day randomisation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Type II Diabetes Mellitus</keyword>
	<keyword>metformin</keyword>
	<keyword>glipizide</keyword>
</DOC>